Home › Funds › Caligan Partners LP › AGIO
Caligan Partners LP position in AGIO
AGIOS PHARMACEUTICALS INC · Health Care
Caligan Partners LP reported holding 90,000 shares of AGIO (AGIOS PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$3.3M, representing 0.20% of its reported portfolio and ranking #24 among its reported holdings. Caligan Partners LP has disclosed AGIO holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Caligan Partners LP's AGIO position evolved
Caligan Partners LP first disclosed a stake in AGIO in Q3 2023 at 4,833 shares (US$120K). The position peaked in Q3 2025 at 975,000 shares, worth US$39.1M. Across 12 filings, Caligan Partners LP increased the stake 7 time(s), trimmed it 2 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 90,000 shares valued at US$3.3M. Notable position changes include a 9042% increase in Q4 2023 (shares rose 31% over the following quarter), a 53% increase in Q2 2025 (shares rose 21% over the following quarter), a 91% trim in Q4 2025 (shares rose 24% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 4.83K | $119.62K | New |
| Q4 2023 | 441.83K | $9.84M | Add |
| Q1 2024 | 484.71K | $14.17M | Add |
| Q2 2024 | 514.71K | $22.19M | Add |
| Q3 2024 | 579.72K | $25.76M | Add |
| Q4 2024 | 626.28K | $20.58M | Add |
| Q1 2025 | 701.28K | $20.55M | Add |
| Q2 2025 | 1.07M | $35.63M | Add |
| Q3 2025 | 975.00K | $39.14M | Reduce |
| Q4 2025 | 90.00K | $2.45M | Reduce |
| Q1 2026 | 90.00K | $3.04M | Hold |
| Q2 2026 | 90.00K | $3.34M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AGIO and 13F data
AGIO (AGIOS PHARMACEUTICALS INC) is a Health Care company. 31 other funds we track also report a position in AGIO — the largest reported positions include Farallon Capital Management (US$219.6M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$219.6M), Lynx1 Capital Management LP (US$126.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AGIO
- Farallon Capital Management 5.92M sh · $219.59M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 5.92M sh · $219.59M · Q2 2026
- Lynx1 Capital Management LP 3.41M sh · $126.51M · Q2 2026
- ARMISTICE CAPITAL, LLC 2.40M sh · $89.06M · Q2 2026
- Erste Asset Management GmbH 2.15M sh · $81.97M · Q2 2026
- ADAR1 Capital Management, LLC 1.29M sh · $47.80M · Q2 2026
- Foresite Capital Management VI LLC 785.00K sh · $29.13M · Q2 2026
- Parkman Healthcare Partners LLC 669.05K sh · $24.83M · Q2 2026
More on Caligan Partners LP
FAQ
How long has Caligan Partners LP held AGIO?
Caligan Partners LP has disclosed AGIO holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Caligan Partners LP's current position in AGIO?
As of Q2 2026, Caligan Partners LP holds 90.00K shares of AGIO (AGIOS PHARMACEUTICALS INC), valued at $3.34M, representing 0.20% of its reported portfolio and ranking #24.
Has Caligan Partners LP been buying or selling AGIO?
In the latest 13F filing (Q2 2026), Caligan Partners LP held unchanged its position in AGIO. The position peaked in Q3 2025 at 975.00K shares.
Which other funds hold AGIO?
Other major institutional holders of AGIO include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., Lynx1 Capital Management LP, among 31 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.